Vmbook Online ordering

Diadexus Inc

Diadexus Inc is a publicly traded company that specializes in the development and commercialization of gene therapies for the treatment of rare and severe neurodegenerative disorders. The company's lead product candidate, DX 101, is a gene therapy for the treatment of Giant Axonal Neuropathy (GAN), a rare inherited neurological disorder that affects both the peripheral and central nervous systems.

Diadexus Inc is listed on the NASDAQ stock exchange under the ticker symbol DDDX. The company's headquarters are located in Gaithersburg, Maryland.

It's important to note that the information provided here is general and for reference only, and should not be considered as investment advice. When considering investing in any publicly traded company, it's always recommended to conduct your own research and consider seeking advice from financial advisors. Also, You can check the official website of Diadexus Inc or their latest financial reports, press releases and SEC filings for more detailed and updated information.